Skip to content
OpenCapital
Get started

Inhibikase Therapeutics, Inc. IKT Q3 2025 earnings

Reported November 14, 2025 · Before market open

Diluted EPS-$0.13In line
EPS estimate-$0.13

Next report

Aug 13, 2026 (in a month)
EPS estimate-$0.09

Versus estimates

Diluted EPS

Q1 2026-$0.10In lineQ4 2025-$0.09Beat by $0.03
Q3 2025-$0.13In line
Q2 2025-$0.11Miss by $0.02Q1 2025-$0.15Miss by $0.04Q4 2024-$0.63Miss by $0.53

Ask the moment Inhibikase Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Inhibikase Therapeutics, Inc. report Q3 2025 earnings?
Inhibikase Therapeutics, Inc. (IKT) reported Q3 2025 earnings on November 14, 2025 before market open.
What were Inhibikase Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Inhibikase Therapeutics, Inc. reported diluted EPS of $-0.13 for Q3 2025.
Did Inhibikase Therapeutics, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.13 by $0.00.
How did Inhibikase Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 80.0% from $-0.65.
Where can I find Inhibikase Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-283075) and the 10-Q periodic report (0001193125-25-283169) directly on SEC EDGAR. The filing index links above go to sec.gov.